Clinical Trial Search

Primary: Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days — -0.71; -0.40 Units on a scale — p=<0.001

Primary: The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days — -0.64; -0.49 Units on a scale — p=0.006

Primary: Minimum Cross-Sectional Area (Amin) Proportion Measured Using Acoustic Rhinometry — 0.760; 0.742; 0.717; 0.795 ratio — p=0.302

Primary: Primary Effectiveness — -0.87; -0.44 score on a scale

Primary: Change in Visual Analog Scale (VAS) From Baseline to 6 Weeks (6-week Value Compared to Baseline Value) — -8; -2 Scale points

Primary: The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days. — -0.68; -0.57 Units on a scale — p=0.102

Primary: Mean Change From Baseline in Daily Reflective Nasal Congestion Score — 2.357; 2.271; -0.394; -0.412 Scores on a scale

Primary: Global Assessment — 1.7; 1.4 units on a scale — p=0.372

Primary: Mean Change From Baseline Over the Entire Treatment Period in the Daily Reflective Nasal Congestion Score — -0.460; -0.499; -0.508; -0.461 Units on a Scale — p=0.4912

Primary: Change in Total Nasal Symptom Score (TNSS) at 4 to 6 Weeks — 3.5 score on a scale

Primary: Change From Baseline in Mean Average Score Using Pittsburgh Insomnia Rating Scale (PIRS) in Q1, Q3, Q17 and Q18 at Day 7 — -0.911; -0.694; -1.032; -1.004 Score on a…

Primary: Total Nasal Symptom Score — 2.0 score on a scale

Primary: Total Nasal Congestion Symptom Score — 94; 70; 75; 68 units on a scale

Primary: Severity of Nasal Obstruction Symptoms at Baseline and Week 12 as Measured by the Total Clinical Score — 3.89; 1.26 Score on a scale

Primary: Change in Nasal Peak Inspiratory Flow (NPIF) — 36.41; 18.71 liters/min

Primary: Anatomical Measures : Cross Sectional Area — 133.22; 116.88; 156.48; 176.12 mm^2 — p=<0.0001

Primary: Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score — -0.45; -1.34 score on a scale — p=<0.0001

Primary: Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms — -0.26; -0.53; -0.56; -0.67 units on a scale

Primary: Improvement of Sleep Associated With the Use of Pseudoephedrine as Compared to the Placebo

Primary: Incidence of Unanticipated Serious Adverse Device Effects — 0 events

Primary: Change in Subjective Nasal Scoring — 0.62; 1.53 score on a scale — p=0.013

Primary: Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score — -0.38; -1.25 score on a scale — p=<0.0001

Primary: Change From Baseline in Congestion/Obstruction Score — -0.56; -0.42 score on a scale — p=0.0007

Primary: IFN-y Protein Response in Mucosal Lining Fluid — NA; 3.29; 9.42; 8.20 pg/hr/ml

Primary: Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score — 75.8; -1.5; -15.4; -27.3 score on a scale — p=0.2968

Primary: The Average Change From Baseline to Endpoint (6 Hours Post-dosing) in Nasal Congestion for Phenylephrine Compared With Placebo — 2.20; 2.20; -0.12; -0.18 Units on a…

Primary: Effectiveness of Oxymetazoline in the Treatment of Rhinitis With Persistent Nasal Obstruction — 1.38; 1.67 units on a scale

Primary: Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms — -0.24; -0.59; -0.68; -0.62 units on a scale

Primary: Change From Baseline in AM/PM Instantaneous Total Nasal Symptom Score (NOW TNSS) Averaged Over Days 1 to 15 — -3.29; -3.36; -2.97; -2.44 units on a scale — p=0.002

Primary: Response — 2; 4; 1; 12 Participants